Background: Up to 20% of saphenous vein grafts (SVG) fail in the 1st yr. The etiology of early failure is not well understood. Methods: We used coronary angiography and intravascular ultrasound (IVUS) to analyze 100 pts (121 lesions) with early (<1 yr) SVG failure and 200 pts (289 lesions) with late (>1yr) SVG failure. IVUS assessment included reference and lesion SVG, lumen, and plaque areas; plaque burden (SVG/plaque area); remodeling (lesion/reference SVG area); and morphology. Results: Risk factors were identical in both groups: smoking (44%), diabetes (36%), hypercholesterolemia (70%), and hypertension (63% early vs 72% late, p = 0.14). Early failure pts had more anginal rest pain (34.3% vs.19.8%). Comparing early to late failure, lesion location was proximal in 62% vs 42% (ostial in 37% vs 18%), mid-segment in 13% vs 29%, distal in 13% vs 20%, and distal anastomosis in 13% vs 5%. Lesion length was similar (9.6 vs 9.27 mm, p= 0.7). The early failure group had smaller references (IVUS and angio: 2.74± 0.86 vs 3.26± 0.83 mm, p< 0.01) and little remodeling at the lesion site. Conversely, late failure lesions had significantly less reference segment plaque burden, but more mobile plaque elements (21.4% vs 0%, p= 0.01) and calcific plaque (17.9 % vs. 0%, p= 0.02). Conclusion: Early SVG failure occurs more often at the ostium. Grafts failing <1yr have more reference segment plaque and less lesion site remodeling suggesting a more aggressive disease process with intrinsic graft fibrosis.
1155-78 Implications and Prevention of Large Periprocedural Myocardial Infarction After Percutaneous Intervention of Diseased Saphenous Vein Grafts and Thrombotic Native Coronary Lesions
Zoran Lasic, Roxana Mehran, Eugenia Nikolsky, Manuela Negoita, Ricardo Costa, David A. Cox, Joseph Babb, Dean Nukta, Luc Bilodeau, Louis Cannon, Thomas D. Stuckey, James Hermiller, Alexandra Lansky, Martin B. Leon, Gregg W. Stone, Lenox Hill Hospital, New York City, NY Background: Peri-procedural myonecrosis after percutaneous coronary intervention (PCI) is especially common after intervention in saphenous vein grafts (SVG) and thrombotic lesions, and is strongly associated with worse short and long-term outcomes, especially when the CPK-MB is >8x normal or Q-wave MI develops. Whether thrombectomy can decrease the incidence of large peri-procedural myocardial infarctions and improve outcomes in these high risk situations is unknown.
Methods:
We analyzed the effectiveness of thrombectomy with the ev3 X-SIZER in preventing large peri-procedural MIs (Q-wave or CK-MB >8x nl) in the multicenter prospective X-TRACT trial, in which 797 pts undergoing PCI of diseased SVGs and thrombus containing native coronary arteries were randomized to thrombectomy vs. control prior to stenting. 
Background:
Paclitaxel, which stabilizes microtubules and renders the affected cell incapable of proliferation and migration, has been shown to reduce neointimal formation. Paclitaxel-loaded stents have been successfully used in the clinical setting to deliver this very potent agent to the vessel wall. There are, however, situations such as in-or persistent restenosis or small vessel angioplasty when a drug eluting stent might not be ideal because of the thrombosis risk or when their use is inappropriate (edge residual stenosis). In this experiment we loaded paclitaxel onto conventional angioplasty balloon and delivered it to human arterial wall ex vivo.
Methods:
Whole angioplasty balloons were inflated and then loaded with paclitaxel by immersing (for 1 hour) into paclitaxel solution (10 mg/ml and 20 mg/ml) spiked with radiolabelledpaclitaxel. After air-drying, the balloons were placed in scintillation fluid and betacounted. Elution of loaded paclitaxel was measured in buffer and blood for up to 10 min. Paclitaxel loaded balloons were placed inside fresh internal mammary arteries (IMA) segment, incubated at 37°C and were inflated at 8 atmospheric pressure for 1 and 10 minutes. Intramural deposition was measured after flushing the vessel segment with 5 mls of blood.
Results:
Paclitaxel was loaded successfully onto conventional angioplasty balloon of various sizes. Corrected for balloon surface area, we achieved paclitaxel loading of 0.22 µg/mm² after immersion in 10mg/ml paclitaxel solution and 0.37 µg/mm² in 20 mg/ml (p=0.005).
There was little paclitaxel elution in blood and in buffer in the first 10 min (6.2% and 9.7% respectively). Further, 34.8% paclitaxel was deposited in the artery wall after 1 minute and 36.7% after 10 minute balloon inflation.
Conclusion:
Paclitaxel can be successfully loaded onto an angioplasty balloon. There was minimal loss of paclitaxel into blood and up to 34.8% delivery efficiency into internal mammary artery after 1 minute balloon inflation. Further studies with this novel drug eluting balloon (DEB) are ongoing to evaluate its effect on smooth muscle cell proliferation in vitro and restenosis in vivo. Restenosis after balloon angioplasty alone may be reduced. 
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